• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

决定消除淋巴丝虫病大规模药物治疗不依从性的因素。

Factors determining noncompliance to mass drug administration for lymphatic filariasis elimination.

作者信息

Nujum Zinia T, Remadevi S, Nirmala C, Rajmohanan K, Indu Ps, Nair S Muraleedharan

机构信息

Department of Community Medicine, Clinical Epidemiology Resource and Training Centre (CERTC), Thiruvananthapuram, Kerala, India.

出版信息

Trop Parasitol. 2012 Jul;2(2):109-15. doi: 10.4103/2229-5070.105175.

DOI:10.4103/2229-5070.105175
PMID:23767017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3680877/
Abstract

Mass Drug Administration (MDA) for Lymphatic Filariasis (LF) elimination has been implemented worldwide and in India with a goal of eliminating the disease by 2020 and 2015 respectively. Compliance to MDA is less than adequate to achieve the goal in the desired time. This study aims to identify the factors related to awareness, acceptability and attitude and the role of certain theoretical constructs of health belief model in determining the compliant behavior to MDA. Within a cross-sectional study done in Thiruvananthapuram district of Kerala, India, undertaken to determine coverage, a comparison was done between compliant and noncompliant individuals. 300 households were selected using cluster sampling technique, for estimation of coverage of MDA. From these households, 99 noncompliant and 70 compliant individuals were selected as cases and controls. The independent factors determining noncompliance were client attitude of not perceiving the need with an adjusted odds ratio (OR) of 2.52 (1.29-4.92), an unfavorable provider attitude with an adjusted OR of 2.14 (1.05-4.35) and low drug administrator acceptability with an adjusted OR of 2.01 (1.01-3.99). In MDA, the person giving the drug to the beneficiary is the most important person, whose attitude and acceptability determines compliance. More rigorous selection and training for capacity building of drug administrators are essential to enhance the compliance level. Alternate drug delivery strategies, besides house to house campaign by voluntary drug administers also needs to be implemented.

摘要

为消除淋巴丝虫病(LF)而开展的群体药物给药(MDA)已在全球和印度实施,目标分别是到2020年和2015年消除该疾病。对MDA的依从性不足以在预期时间内实现目标。本研究旨在确定与认知、可接受性和态度相关的因素,以及健康信念模型的某些理论结构在确定对MDA的依从行为方面的作用。在印度喀拉拉邦特里凡得琅地区进行的一项横断面研究中,为确定覆盖率,对依从和不依从个体进行了比较。使用整群抽样技术选取了300户家庭,以估计MDA的覆盖率。从这些家庭中,选取了99名不依从个体和70名依从个体作为病例和对照。决定不依从的独立因素包括:客户认为没有必要的态度,调整后的比值比(OR)为2.52(1.29 - 4.92);提供者态度不佳,调整后的OR为2.14(1.05 - 4.35);药物管理人员的可接受性低,调整后的OR为2.01(1.01 - 3.99)。在MDA中,给受益人给药的人是最重要的人,其态度和可接受性决定了依从性。对药物管理人员进行更严格的选拔和能力建设培训对于提高依从水平至关重要。除了由志愿药物管理人员进行逐户宣传外,还需要实施替代药物递送策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eab/3680877/7f1441335807/TP-2-109-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eab/3680877/7f1441335807/TP-2-109-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eab/3680877/7f1441335807/TP-2-109-g008.jpg

相似文献

1
Factors determining noncompliance to mass drug administration for lymphatic filariasis elimination.决定消除淋巴丝虫病大规模药物治疗不依从性的因素。
Trop Parasitol. 2012 Jul;2(2):109-15. doi: 10.4103/2229-5070.105175.
2
Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India.印度喀拉拉邦一个地区开展淋巴丝虫病大规模药物治疗的覆盖范围和依从性。
Int Health. 2011 Mar;3(1):22-6. doi: 10.1016/j.inhe.2010.12.001.
3
Risk Factors of Noncompliance to Preventive Mass Drug Administration for Eliminating Lymphatic Filariasis: A Case-Control Study in Jawi District, Northwest Ethiopia.消除淋巴丝虫病预防性群体服药不依从的风险因素:埃塞俄比亚西北部贾维区的一项病例对照研究
J Trop Med. 2022 Sep 21;2022:4792280. doi: 10.1155/2022/4792280. eCollection 2022.
4
Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance.印度一个沿海邦开展的消除淋巴丝虫病群体药物给药:关于覆盖范围和依从性障碍的研究
Infect Dis Poverty. 2014 Sep 1;3:31. doi: 10.1186/2049-9957-3-31. eCollection 2014.
5
Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study.印度中部那格浦尔市消除淋巴丝虫病群体服药的覆盖情况:一项混合方法研究
J Family Med Prim Care. 2019 Sep 30;8(9):3009-3014. doi: 10.4103/jfmpc.jfmpc_503_19. eCollection 2019 Sep.
6
Is the coverage of mass-drug-administration adequate for elimination of Bancroftian filariasis? An experience from West Bengal, India.群体服药对消除班氏丝虫病的覆盖率是否足够?来自印度西孟加拉邦的经验。
Trop Parasitol. 2015 Jan-Jun;5(1):42-9. doi: 10.4103/2229-5070.149921.
7
Coverage of mass drug administration (MDA) and operational issues in elimination of lymphatic filariasis in selected districts of Jharkhand, India.印度恰尔肯德邦部分地区大规模药物给药(MDA)的覆盖情况及消除淋巴丝虫病的操作问题
J Family Med Prim Care. 2023 Jan;12(1):111-116. doi: 10.4103/jfmpc.jfmpc_1149_22. Epub 2023 Feb 15.
8
Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India.印度西孟加拉邦布尔杜万区为消除淋巴丝虫病开展群体服药的覆盖率、知晓率及依从情况
J Health Popul Nutr. 2013 Jun;31(2):171-7. doi: 10.3329/jhpn.v31i2.16380.
9
Outcome assessment of the implementation of Mass Drug Administration against lymphatic filariasis in Kalaburagi (Gulbarga) Karnataka, India: A cross-sectional survey.印度卡纳塔克邦卡拉布尔吉(古尔伯加)开展的针对淋巴丝虫病群体服药措施实施情况的结果评估:一项横断面调查
J Vector Borne Dis. 2024;61(4):581-586. doi: 10.4103/JVBD.jvbd_67_24. Epub 2024 Nov 26.
10
Factors determining non-compliance to mass drug administration for lymphatic filariasis elimination in endemic districts of Nepal.尼泊尔流行地区影响大规模药物管理以消除淋巴丝虫病依从性的因素。
J Nepal Health Res Counc. 2014 May-Aug;12(27):124-9.

引用本文的文献

1
Clinical profile and Mass Drug Administration coverage in patients with lymphatic filariasis: A descriptive study.淋巴丝虫病患者的临床特征与群体服药覆盖率:一项描述性研究。
J Family Med Prim Care. 2025 Jul;14(7):2902-2907. doi: 10.4103/jfmpc.jfmpc_2056_24. Epub 2025 Jul 21.
2
Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review.与大规模药物治疗丝虫病可接受性相关的因素:系统评价。
Int J Environ Res Public Health. 2022 Oct 10;19(19):12971. doi: 10.3390/ijerph191912971.
3
Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya.

本文引用的文献

1
Lymphatic Filariasis in India : Problems, Challenges and New Initiatives.印度的淋巴丝虫病:问题、挑战与新举措
Med J Armed Forces India. 2006 Oct;62(4):359-62. doi: 10.1016/S0377-1237(06)80109-7. Epub 2011 Jul 21.
2
Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India.印度喀拉拉邦一个地区开展淋巴丝虫病大规模药物治疗的覆盖范围和依从性。
Int Health. 2011 Mar;3(1):22-6. doi: 10.1016/j.inhe.2010.12.001.
3
Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008.
为消除淋巴丝虫病而提高群体治疗覆盖率面临的实施挑战与机遇:肯尼亚沿海地区社区药品分发人员的看法与经验
PLoS Negl Trop Dis. 2020 Dec 28;14(12):e0009012. doi: 10.1371/journal.pntd.0009012. eCollection 2020 Dec.
4
Fecundity of adult female worms were affected when Brugia malayi infected Mongolian gerbils were immunized with a multivalent vaccine (rBmHAXT) against human lymphatic filarial parasite.当用针对人类淋巴丝虫寄生虫的多价疫苗(rBmHAXT)对感染马来布鲁线虫的蒙古沙鼠进行免疫时,成年雌虫的繁殖力受到影响。
Acta Trop. 2020 Aug;208:105487. doi: 10.1016/j.actatropica.2020.105487. Epub 2020 May 11.
5
Epidemiological screening and xenomonitoring for human lymphatic filariasis infection in select districts in the states of Maharashtra and Karnataka, India.印度马哈拉施特拉邦和卡纳塔克邦部分地区人体淋巴丝虫病感染的流行病学筛查和外来监测。
Parasitol Res. 2019 Mar;118(3):1045-1050. doi: 10.1007/s00436-019-06205-0. Epub 2019 Jan 21.
6
Perceived threat and benefit toward community compliance of filariasis' mass drug administration in Pekalongan district, Indonesia.印度尼西亚北加浪岸地区对丝虫病群体药物管理社区依从性的感知威胁和益处。
Risk Manag Healthc Policy. 2018 Oct 23;11:189-197. doi: 10.2147/RMHP.S172860. eCollection 2018.
7
Evaluating the Vaccine Potential of a Tetravalent Fusion Protein (HAXT) Vaccine Antigen Against Lymphatic Filariasis in a Mouse Model.在小鼠模型中评估四价融合蛋白(HAXT)疫苗抗原针对淋巴丝虫病的疫苗潜力。
Front Immunol. 2018 Jul 2;9:1520. doi: 10.3389/fimmu.2018.01520. eCollection 2018.
8
Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates.开发针对人体丝虫病的预防性疫苗的前景 - 对非人类灵长类动物的保护作用评估。
Int J Parasitol. 2018 Aug;48(9-10):773-783. doi: 10.1016/j.ijpara.2018.04.002. Epub 2018 Jun 6.
9
Knowledge, attitudes and perceptions regarding lymphatic filariasis: study on systematic noncompliance with mass drug administration.关于淋巴丝虫病的知识、态度和认知:对大规模药物管理系统性不依从的研究
Rev Inst Med Trop Sao Paulo. 2017 Apr 20;59:e23. doi: 10.1590/S1678-9946201759023.
10
Reaching endpoints for lymphatic filariasis elimination- results from mass drug administration and nocturnal blood surveys, South Gujarat, India.印度古吉拉特邦南部通过群体药物给药和夜间血液调查实现淋巴丝虫病消除目标的结果
PLoS Negl Trop Dis. 2017 Apr 3;11(4):e0005476. doi: 10.1371/journal.pntd.0005476. eCollection 2017 Apr.
2008 年印度奥里萨邦大规模药物治疗淋巴丝虫病方案的依从性预测因素。
Trop Med Int Health. 2010 Feb;15(2):224-31. doi: 10.1111/j.1365-3156.2009.02443.x. Epub 2009 Dec 9.
4
Mass drug administration against filariasis in India: perceptions and practices in a rural community in Kerala.印度针对丝虫病的群体药物给药:喀拉拉邦一个农村社区的认知与实践
Ann Trop Med Parasitol. 2009 Oct;103(7):617-24. doi: 10.1179/000349809X12459740922255.
5
Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.印度奥里萨邦消除淋巴丝虫病项目期间群体服药的覆盖率、依从性及一些操作问题
Trop Med Int Health. 2004 Jun;9(6):702-9. doi: 10.1111/j.1365-3156.2004.01247.x.
6
Two views of risky sexual practices among northern Thai males: the Health Belief Model and the Theory of Reasoned Action.泰国北部男性危险性行为的两种观点:健康信念模式与理性行动理论。
J Health Soc Behav. 1995 Jun;36(2):195-212.
7
Re-assessing the global prevalence and distribution of lymphatic filariasis.重新评估淋巴丝虫病的全球流行率和分布情况。
Parasitology. 1996 Apr;112 ( Pt 4):409-28. doi: 10.1017/s0031182000066646.
8
Role of patient compliance in clinical pharmacokinetics. A review of recent research.患者依从性在临床药代动力学中的作用。近期研究综述。
Clin Pharmacokinet. 1994 Sep;27(3):202-15. doi: 10.2165/00003088-199427030-00004.
9
Screening for noncompliance among patients with hypertension: is self-report the best available measure?高血压患者不依从性的筛查:自我报告是最佳可用测量方法吗?
Med Care. 1981 Oct;19(10):1061-4. doi: 10.1097/00005650-198110000-00008.
10
Can simple clinical measurements detect patient noncompliance?简单的临床测量能否检测出患者的不依从性?
Hypertension. 1980 Nov-Dec;2(6):757-64. doi: 10.1161/01.hyp.2.6.757.